[Up-to-date on the treatment of benign prostatic hyperplasia. Which adenoma to treat and how to do it?]

Rev Med Interne. 2014 Mar;35(3):189-95. doi: 10.1016/j.revmed.2013.10.007. Epub 2013 Nov 18.
[Article in French]

Abstract

Benign prostatic hyperplasia is a state of the nature rather than a disease. It affects mainly men over 50 years and represents a public health problem. A literature review on the therapeutic management of benign prostatic hyperplasia was carried out from a selection of publications with the highest level of evidence. Medical treatment is based on herbal medicine, alpha-blockers and 5-alpha-reductase inhibitors. Surgical treatment is used in case of complications or failure of medical management. Surgical options are numerous. Transurethral prostate resection and prostate adenomectomy are the most usual procedures. Due to their significant morbidity, other less invasive procedures have recently been developed. The choice of treatment will depend on prostate volume and anatomy and patient's comorbidities.

Keywords: 5-alpha-reductase inhibitors; Adénome prostatique; Adénomectomie prostatique; Alpha-blockers; Alpha-bloquants; Benign prostatic hyperplasia; Hyperplasie bénigne de la prostate; Inhibiteurs de la 5-alpha-réductase; Prostate adenoma; Prostate adenomectomy; Résection endoscopique de prostate; Transurethral prostate resection.

Publication types

  • English Abstract
  • Review

MeSH terms

  • 5-alpha Reductase Inhibitors / therapeutic use
  • Adenoma / diagnosis*
  • Adenoma / therapy*
  • Adrenergic alpha-1 Receptor Antagonists / therapeutic use
  • Cholinergic Antagonists / therapeutic use
  • Diagnosis, Differential
  • Humans
  • Male
  • Phytotherapy / methods
  • Prostatic Hyperplasia / diagnosis*
  • Prostatic Hyperplasia / therapy*
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / therapy*
  • Urologic Surgical Procedures, Male / methods
  • Urological Agents / therapeutic use
  • Watchful Waiting

Substances

  • 5-alpha Reductase Inhibitors
  • Adrenergic alpha-1 Receptor Antagonists
  • Cholinergic Antagonists
  • Urological Agents